Survival in neutropenic patients with severe sepsis or septic shock

被引:195
|
作者
Legrand, Matthieu [1 ]
Max, Adeline [1 ]
Peigne, Vincent [1 ]
Mariotte, Eric [1 ]
Canet, Emmanuel [1 ]
Debrumetz, Alexandre [1 ]
Lemiale, Virginie [1 ]
Seguin, Amelie [1 ]
Darmon, Michael [1 ]
Schlemmer, Benoit
Azoulay, Elie [1 ]
机构
[1] St Louis Hosp, AP HP, Med Intens Care Unit, Paris, France
关键词
diagnosis; management; neutropenia; outcomes; sepsis; shock; INTENSIVE-CARE-UNIT; MECHANICAL VENTILATORY SUPPORT; INFECTIOUS-DISEASES SOCIETY; DIFFUSE ALVEOLAR HEMORRHAGE; ILL CANCER-PATIENTS; ANTIMICROBIAL AGENTS; FEBRILE NEUTROPENIA; PROGNOSTIC-FACTORS; SOFA SCORE; MANAGEMENT;
D O I
10.1097/CCM.0b013e31822b50c2
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To determine whether the survival gains achieved in critically ill cancer patients in recent years exist in the subset with neutropenia and severe sepsis or septic shock. Design: Retrospective 11-yr study (1998-2008). Setting: Medical intensive care unit in a teaching hospital. Patients: Four hundred twenty-eight intensive care unit patients with cancer, neutropenia, and severe sepsis or septic shock. The primary outcome was hospital mortality. Results: The main underlying diseases were acute leukemia (35.7%), lymphoma (31.7%), and solid tumors (16.5%). Two hundred thirty-seven (55.5%) patients had microbiologically documented infections, 141 (32.9%) clinically documented infections, and 50 (11.9%) fever of unknown origin. Acute noninfectious conditions were diagnosed in 175 of 428 (41%) patients, including 26 of 50 (52%) patients with fever of unknown origin, 66 of 141 (47%) patients with clinically documented infections, and 83 of 237 (35%) patients with microbiologically documented infections. Early indwelling catheter removal was performed routinely in the 107 (25%) patients without clinical evidence of a septic focus at intensive care unit admission. Early beta-lactam plus aminoglycoside therapy was used in 391 (91.3%) patients. Hospital mortality was 49.8%. Hospital mortality decreased from 58.7% (108 of 184) in 1998-2003 to 43% in 2004-2008 (105 of 244, p = .006). Multivariate analysis identified nine independent predictors of hospital mortality, of which six were associated with higher mortality (older age; need for vasopressors; neurologic, respiratory, or hepatic dysfunction; and acute noninfectious condition) and three with lower mortality (intensive care unit admission after 2003, combination antibiotic therapy including an aminoglycoside, and early indwelling catheter removal). Conclusion: In neutropenic patients with severe sepsis or septic shock, survival improved over time. Aminoglycoside use and early catheter removal in patients with undocumented sepsis may improve survival. Acute noninfectious conditions are associated with increased mortality, underlining the need for thorough and repeated clinical assessments. (Crit Care Med 2012; 40:43-49)
引用
收藏
页码:43 / 49
页数:7
相关论文
共 50 条
  • [31] Systolic blood pressure variability in patients with early severe sepsis or septic shock: a prospective cohort study
    Tang, Yi
    Sorenson, Jeff
    Lanspa, Michael
    Grissom, Colin K.
    Mathews, V. J.
    Brown, Samuel M.
    BMC ANESTHESIOLOGY, 2017, 17
  • [32] IMPACT OF SEPSIS BUNDLE STRATEGY ON OUTCOMES OF PATIENTS SUFFERING FROM SEVERE SEPSIS AND SEPTIC SHOCK IN CHINA
    Wang, Zhen
    Xiong, Yingxia
    Schorr, Christa
    Dellinger, R. P.
    JOURNAL OF EMERGENCY MEDICINE, 2013, 44 (04) : 735 - 741
  • [33] Increased DNA damage and increased apoptosis and necrosis in patients with severe sepsis and septic shock
    Bahar, Ilhan
    Elay, Gulseren
    Baskol, Gulden
    Sungur, Murat
    Donmez-Altuntas, Hamiyet
    JOURNAL OF CRITICAL CARE, 2018, 43 : 271 - 275
  • [34] Propensity-Based Study of Aminoglycoside Nephrotoxicity in Patients with Severe Sepsis or Septic Shock
    Picard, W.
    Bazin, F.
    Clouzeau, B.
    Bui, H. -N.
    Soulat, M.
    Guilhon, E.
    Vargas, F.
    Hilbert, G.
    Bouchet, S.
    Gruson, D.
    Moore, N.
    Boyer, A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (12) : 7468 - 7474
  • [35] Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock
    Mathias W. Pletz
    Frank Bloos
    Olaf Burkhardt
    Frank M. Brunkhorst
    Stefanie M. Bode-Böger
    Jens Martens-Lobenhoffer
    Mark W. Greer
    Heino Stass
    Tobias Welte
    Intensive Care Medicine, 2010, 36 : 979 - 983
  • [36] Albumin Replacement in Patients with Severe Sepsis or Septic Shock
    Caironi, Pietro
    Tognoni, Gianni
    Masson, Serge
    Fumagalli, Roberto
    Pesenti, Antonio
    Romero, Marilena
    Fanizza, Caterina
    Caspani, Luisa
    Faenza, Stefano
    Grasselli, Giacomo
    Iapichino, Gaetano
    Antonelli, Massimo
    Parrini, Vieri
    Fiore, Gilberto
    Latini, Roberto
    Gattinoni, Luciano
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (15) : 1412 - 1421
  • [37] The impact of a multifaceted intervention including sepsis electronic alert system and sepsis response team on the outcomes of patients with sepsis and septic shock
    Arabi, Yaseen M.
    Al-Dorzi, Hasan M.
    Alamry, Ahmed
    Hijazi, Ra'ed
    Alsolamy, Sami
    Al Salamah, Majid
    Tamim, Hani M.
    Al-Qahtani, Saad
    Al-Dawood, Abdulaziz
    Marini, Abdellatif M.
    Al Ehnidi, Fatimah H.
    Mundekkadan, Shihab
    Matroud, Amal
    Mohamed, S. Mohamed
    Taher, Saadi
    ANNALS OF INTENSIVE CARE, 2017, 7
  • [38] Timeliness of antibiotics for patients with sepsis and septic shock
    Schiakel, Alichiel
    Panday, Rishi S. Nannan
    Wiersinga, W. Joost
    Nanavakkara, Prabath W. B.
    JOURNAL OF THORACIC DISEASE, 2020, 12 : S66 - S71
  • [39] Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock
    Pletz, Mathias W.
    Bloos, Frank
    Burkhardt, Olaf
    Brunkhorst, Frank M.
    Bode-Boeger, Stefanie M.
    Martens-Lobenhoffer, Jens
    Greer, Mark W.
    Stass, Heino
    Welte, Tobias
    INTENSIVE CARE MEDICINE, 2010, 36 (06) : 979 - 983
  • [40] Filgrastim in patients with pneumonia and severe sepsis or septic shock
    Wunderink, RG
    Leeper, KV
    Schein, R
    Nelson, S
    DeBoisblanc, BP
    Fotheringham, N
    Logan, E
    CHEST, 2001, 119 (02) : 523 - 529